{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:16:38Z","timestamp":1792030598489,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17lk0103012"],"award-info":[{"award-number":["JP17lk0103012"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.omtm.2021.02.018","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T05:38:15Z","timestamp":1614404295000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II"],"prefix":"10.1016","volume":"21","author":[{"given":"Joo-Hyun","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomichi","family":"Kosuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-1593","authenticated-orcid":false,"given":"Haruo","family":"Shintaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3004-1412","authenticated-orcid":false,"given":"Torayuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2021.02.018_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.omtm.2021.02.018_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.08.009","article-title":"Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations\u2014neurological signs and symptoms","volume":"122S","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.02.018_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/21678707.2017.1296761","article-title":"Presentation and treatments for mucopolysaccharidosis type II (MPS II; Hunter syndrome)","volume":"5","author":"Stapleton","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.omtm.2021.02.018_bib4","first-page":"100630","article-title":"Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): contribution of genotype to cognitive developmental course","volume":"24","author":"Seo","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2021.02.018_bib5","series-title":"Practical Guideline for the Management of Mucopolysaccharidosis (MPS) Type II 2019 [Japanese]","year":"2019"},{"key":"10.1016\/j.omtm.2021.02.018_bib6","doi-asserted-by":"crossref","first-page":"e30341","DOI":"10.1371\/journal.pone.0030341","article-title":"CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder","volume":"7","author":"Calias","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2021.02.018_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2021.02.018_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/jhg.2016.133","article-title":"Comparative study of idursulfase beta and idursulfase in\u00a0vitro and in\u00a0vivo","volume":"62","author":"Kim","year":"2017","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.omtm.2021.02.018_bib9","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s10545-018-0221-0","article-title":"The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology","volume":"41","author":"Sohn","year":"2018","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2021.02.018_bib10","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2021.02.018_bib11","series-title":"The Guide of Kyoto Scale of Psychological Development 2001 [Japanese].","author":"Ikuzawa","year":"2001"},{"key":"10.1016\/j.omtm.2021.02.018_bib12","first-page":"28","article-title":"Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II","volume":"12","author":"Ngu","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2021.02.018_bib13","first-page":"103","article-title":"Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment","volume":"5","author":"Hendriksz","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2021.02.018_bib14","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1073\/pnas.252784899","article-title":"Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB","volume":"100","author":"Ohmi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2021.02.018_bib15","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jnr.21134","article-title":"Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB","volume":"85","author":"Villani","year":"2007","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.omtm.2021.02.018_bib16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/BF00992503","article-title":"GM2 ganglioside and pyramidal neuron dendritogenesis","volume":"20","author":"Walkley","year":"1995","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.omtm.2021.02.018_bib17","first-page":"1","article-title":"A cerebrospinal fluid collection study in pediatric and adult patients with Hunter syndrome","volume":"3","author":"Hendriksz","year":"2015","journal-title":"J.\u00a0Inborn Errors Metab. Screen."},{"key":"10.1016\/j.omtm.2021.02.018_bib18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1\/2 trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.02.018_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2021.02.018_bib20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ymgme.2012.12.010","article-title":"Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings","volume":"108","author":"Tajima","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.02.018_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-018-0816-4","article-title":"Status of newborn screening and follow up investigations for mucopolysaccharidoses I and II in Taiwan","volume":"13","author":"Chuang","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"issue":"Suppl 2","key":"10.1016\/j.omtm.2021.02.018_bib22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13052-018-0552-3","article-title":"Newborn screening in mucopolysaccharidoses","volume":"44","author":"Donati","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.omtm.2021.02.018_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.braindev.2015.10.010","article-title":"Developmental assessment of VLBW infants at 18\u00a0months of age: A comparison study between KSPD and Bayley III","volume":"38","author":"Kono","year":"2016","journal-title":"Brain Dev."},{"key":"10.1016\/j.omtm.2021.02.018_bib24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2016.05.003","article-title":"Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: genetic, pathological, and structural studies on iduronate-2-sulfatase","volume":"118","author":"Kosuga","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.02.018_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1399-0004.2011.01641.x","article-title":"Identification of 11 novel mutations in 49 Korean patients with mucopolysaccharidosis type II","volume":"81","author":"Sohn","year":"2012","journal-title":"Clin. Genet."},{"key":"10.1016\/j.omtm.2021.02.018_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/adc.79.3.237","article-title":"Mutation analysis in 57 unrelated patients with MPS II (Hunter\u2019s disease)","volume":"79","author":"Vafiadaki","year":"1998","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.omtm.2021.02.018_bib27","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cca.2012.01.012","article-title":"An improved method for glycosaminoglycan analysis by LC-MS\/MS of urine samples collected on filter paper","volume":"413","author":"Auray-Blais","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.omtm.2021.02.018_bib28","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1373\/clinchem.2010.161141","article-title":"Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry","volume":"57","author":"Zhang","year":"2011","journal-title":"Clin. Chem."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:30:15Z","timestamp":1762421415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050121000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":28,"alternative-id":["S2329050121000334"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2021.02.018","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2021.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}]}}